Skip to main content
Quest Diagnostics

Post-induction Minimal Residual Disease Defined by Next-Generation Sequencing Predicts Poorer Clinical Outcomes in Patients with Acute Myeloid Leukemiag

2022  USCAP (United States and Canadian Academy of Pathology 112th Annual Meeting)

March 19-24, 2022, Los Angeles, CA

Poster presentation: Post-induction Minimal Residual Disease Defined by Next-Generation Sequencing Predicts Poorer Clinical Outcomes in Patients with Acute Myeloid Leukemiag

Authors: Li Y, Solis-Ruiz J, Tong CH,  Mohebnasab M,  Racke FK,  Lacbawan FL, Press R

Specialties: Oncology, Genetics

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.